The patent challenges of the Indian company set to become the world’s biggest biosimilars business

In an exclusive interview Biocon Biologics’ chief IP counsel explains the issues that he and his team focus on – and how an upcoming, big-ticket merger will lead to change

Unlock unlimited access to all IAM content